Todd Pettingill
Corporate Officer/Principal at OMNIAB, INC.
Profile
Todd Pettingill is currently the Vice President of Business Development and Strategy at OmniAb Operations, Inc. and OmniAb, Inc. He previously worked as a Senior Manager of Corporate Development at Ligand Pharmaceuticals, Inc. Mr. Pettingill received his undergraduate degree from Brigham Young University and his MBA from UCLA Anderson School of Management.
Todd Pettingill active positions
Companies | Position | Start |
---|---|---|
OMNIAB, INC. | Corporate Officer/Principal | - |
OmniAb Operations, Inc.
OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Corporate Officer/Principal | - |
Former positions of Todd Pettingill
Companies | Position | End |
---|---|---|
LIGAND PHARMACEUTICALS INCORPORATED | Investor Relations Contact | - |
Training of Todd Pettingill
UCLA Anderson School of Management | Masters Business Admin |
Brigham Young University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
OMNIAB, INC. | Commercial Services |
Private companies | 1 |
---|---|
OmniAb Operations, Inc.
OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Health Technology |
- Stock Market
- Insiders
- Todd Pettingill